The big news affecting BPTS stock today comes from a Phase 2/3 study of Sarconeos as a treatment for severe respiratory failure in patients suffering from Covid-19. The company intends to present this data at the 21st Lung Science Conference starting today.
Stanislas Veillet, CEO of Biophytis, said the following in a press release:
“Sarconeos (BIO101) is the only innovative drug candidate in Europe or the United States directly targeting respiratory failure that has demonstrated clinical efficacy in hospitalized patients with hypoxemia caused by COVID-19 as well as a very good safety profile.”
The 21st Lung Science Conference starts today and will last through Sunday. The company intends to release a poster on its website covering the data once the conference is complete.
BPTS Stock Movement on Thursday
With the positive clinical trial news today, shares of BPTS stock are seeing major movement. As of this writing, about 1.5 million shares of the company’s stock have been traded. To put that in perspective, the company’s daily average trading volume is roughly 809,000 shares.
BPTS stock is up 27.8% in pre-market trading on Thursday.
Investors looking for even more of the latest stock market news are in luck!
We’ve got all the hottest stock stories worth knowing about on Thursday! Among that is what’s moving shares of Toro (NASDAQ:TORO) stock, the biggest pre-market stock movers this morning, and more. You can catch up on all of that news at the following links!
More Thursday Stock Market News
- Why Is Toro (TORO) Stock Up 38% Today?
- Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
- Why AMC Stock Is a ‘Zombie’ in the Market Right Now
On Penny Stocks and Low-Volume Stocks: With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That’s because these “penny stocks” are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com’s writers disclose this fact and warn readers of the risks.
On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.